Primary source: View
The EMA's latest update to the additional monitoring list specifies that newly added medicines must now include an inverted black triangle and standard explanatory statement in their package leaflet and Summary of Product Characteristics (SmPC). MAHs must check for additions or removals and adjust labeling according to these changes.
This regulatory action directly impacts the labeling requirements and increases the monitoring intensity for signal management for certain medicines in the EU, thus enhancing patient safety.
MAHs should verify their product's status on the additional monitoring list and ensure compliance with labeling requirements for any additions or removals during their next regulatory submission.
Regulatory Intelligence Lead
As needed, with particular attention to subsequent updates to regulatory submissions.
MAHs should check if their products have been added to or removed from the additional monitoring list. For new additions, the inverted black triangle and standard explanatory statement must be added to the product information during the next regulatory submission. For removals, the triangle should be removed. This change directly impacts labeling and signal management monitoring intensity.
MAHs should verify their product's status on the additional monitoring list and ensure compliance with labeling requirements for any additions or removals during their next regulatory submission.
Medicines added to the additional monitoring list must display an inverted black triangle and a standard explanatory statement in their documentation. Marketing Authorization Holders (MAHs) need to ensure these updates are implemented during their next regulatory submission. Conversely, products removed from the list are required to remove the triangle from their labeling.
What changed: The EMA's latest update to the additional monitoring list specifies that newly added medicines must now include an inverted black triangle and standard explanatory statement in their package leaflet and Summary of Product Characteristics (SmPC). MAHs must check for additions or removals and adjust labeling according to these changes.
Why it matters: This regulatory action directly impacts the labeling requirements and increases the monitoring intensity for signal management for certain medicines in the EU, thus enhancing patient safety.
Practical implication: MAHs should verify their product's status on the additional monitoring list and ensure compliance with labeling requirements for any additions or removals during their next regulatory submission.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
